arterial wall thickening atherosclerosis
Conditions
Interventions
3 months treatment with atorvastatin 40 mg 1 tablet daily
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Aged 50 years or older 2. CKD stages 3 and 4 (eGFR: 15-60 ml min-1)
Exclusion criteria
Exclusion criteria: 1. Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator. 2. Standard contra-indications to 18F-FDG PET, and CT based on physicians experience and current practices 3. Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study. 4. Planned radiation exposure in the next year due to participation in a research project with radiation exposure or for clinical reasons. 5. Clinical signs of acute infection and/or CRP>10 6. History of MI/Stroke or known coronary artery disease 7. Already receiving lipid lowering treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in target-to-background ratio (TBR) in patients with CKD before and after statin therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| - Monocyte subtyping will be assessed by FACS analysis - Monocyte expression of genes involved in inflammation - Trans endothelial migration will be assessed according to standard procedures at Sanquin as described in van Buul et al (16). - In vitro cytokine production will be assessed using isolated monocytes of subjects. Monocytes will be stimulized with LPS, assessing production of inflammatory cytokines (Il6, TNF*) - Epigenetic changes will be assessed by looking at H3K4 methylation at target genes assessed in the previous steps. | — |
Countries
Netherlands
Outcome results
None listed